Bisphosphonate Associated Atypical Femur
Fracture and Contralateral Impending Atypical
Femur Fracture in a Pediatric Patient with
Osteogenesis Imperfecta: A Case Report
Benjamin Albertson, MD; Taylor Polander, MD; Selina Silva, MD
Department of Orthopaedics & Rehabilitation, The University of New Mexico Health Sciences Center,
Albuquerque, New Mexico.
Corresponding Author Benjamin Albertson, MD. Department of Orthopaedics & Rehabilitation, MSC10 5600,
1 University of New Mexico, Albuquerque, NM 87131 (email: balbertson@salud.unm.edu).
Funding The authors received no financial support for the research, authorship, and publication of this article.
Conflict of Interest The authors report no conflict of interest.
Informed Consent The patient and their guardian were informed that the data concerning their case would be
submitted for publication, and they both provided verbal consent.

ABSTRACT
Atypical femur fractures are rare, low-energy
fractures that involve a specific constellation of
radiographic findings. These fractures have been well
described in adult osteoporotic patients on long-term
bisphosphonates; however, little to no literature exists
on atypical femur fractures in pediatric patients on
long-term bisphosphonates. The use of bisphosphonates
as treatment of osteogenesis imperfecta is common to
reduce fracture rate and improve bone mineral density.
We describe a 15-year-old adolescent boy with type I
osteogenesis imperfecta on long-term bisphosphonate
therapy. He presented with an atypical right femur
fracture and an impending left femur fracture. To the
authors’ knowledge, these findings represent the first
case of an atypical femur fracture with a contralateral
impending atypical femur fracture in a pediatric
patient on long-term bisphosphonate treatment. This
case highlights the importance of evaluating pediatric
patients for bisphosphonate-associated complications,
as is typical in adult patients. Physicians should carefully
weigh the risks and benefits of bisphosphonate therapy
in pediatric patients to better understand the potential
adverse effects.
Keywords: Osteogenesis Imperfecta, Bisphosphonates,
Subtrochanteric Fractures, Pediatrics

INTRODUCTION
Osteogenesis imperfecta (OI) is a genetic disorder
affecting type I collagen production, resulting in bone
fragility. OI has been associated with several genes,
most commonly COL1A1 and COL1A2. There are four
common types of OI. Type I includes minimal long-bone
deformities or issues with mobility, type II is lethal, type
III is the most severe and survivable form of the disease
with skeletal deformities and limited ambulation, and
type IV is of moderate severity.1
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Bone fragility caused by OI typically results in
fractures throughout the patient’s life. The most
common medical treatment for children with recurrent
fractures is bisphosphonate therapy, which is typically
continued throughout skeletal maturity. Bisphosphonate
therapy has been used to treat children with OI for
30 years, with increasing acceptance.2 The goal of
bisphosphonate therapy is to improve bone mineral
density and bone pain, decrease the incidence of
fractures and skeletal deformity, and increase functional
independence in patients.
Long-term bisphosphonate therapy in adults has
been linked to atypical femur fractures, and risks of
these fractures appear to increase drastically with
prolonged usage.2 It is currently recommended that
osteoporotic adults limit bisphosphonate use to 5 years
to avoid the increased risk of atypical femur fractures.2
Atypical femur fractures are defined by meeting at least
four out of the five criteria: minimal trauma, transverse
fracture line through the lateral cortex, complete
fracture often associated with medial spike, noncomminuted or minimally comminuted fracture, and
periosteal or endosteal thickening of the lateral cortex.3
There are a small number of case reports of
suspected bisphosphonate-associated atypical
femur fractures in children with OI.2-5 We describe an
adolescent boy with OI on long-term bisphosphonate
therapy. He sustained an atypical subtrochanteric femur
fracture with a contralateral impending atypical femur
fracture. To our knowledge, this is the first case report
describing atypical femur fractures in a patient with
type I OI.

CASE REPORT
A 15-year-old adolescent boy with a history of type
I OI presented to our institution after tripping over a
step while hiking. He fell on the right side of his body,

A

Figure 1. A transverse atypical
subtrochanteric fracture of the right
femur with lateral cortical thickening,
small medial spike, lack of comminution,
and intramedullary canal narrowing,
which is consistent with a cortical stress
response to increased stress from longterm bisphosphonate use. Sequelae of
prior right femoral shaft open reduction
internal fixation with residual screw holes
are visible distal to the fracture.
sustaining a right subtrochanteric femur fracture and
a right proximal humerus fracture. The patient had a
history of multiple fractures, including right and left
femur fractures in 2014 and 2007, respectively. The prior
right femur fracture was treated with open reduction
and plating, with subsequent removal of hardware. The
left femur fracture was treated with a closed reduction
and hip spica casting. Before his most recent fall, he
denied any prior pain in his right and left hip and legs.
He had been on bisphosphonate therapy for 12 years,
and at the time of injury, was being treated with IV
Palmidronate infusions every 4 months.
Upon presentation to our institution, radiographs of
the right femur were obtained. The patient was found
to have an atypical transverse femur fracture of the
right subchondral femur with lateral cortical thickening
(Figure 1). The patient’s right proximal humerus
fracture was assessed radiographically and treated
nonoperatively with a cuff and collar sling. Radiographs
of the left femur were obtained, owing to the atypical
appearance of the right subtrochanteric femur fracture
and the history of long-term bisphosphonate use.
Radiographs showed considerable lateral cortical
beaking with transverse lucency through the lateral
cortex in the subtrochanteric region (Figures 2A and
2B). Considerable deformity to the left femur was
evident, which was secondary to prior fracture.

B

Figure 2. A) Left femur with transverse subtrochanteric
lucency within the lateral cortex and surrounding
lateral cortical thickening, and a medial cortical stress
reaction. B) Zebra lines visible within the distal femur
and sequelae of prior left femoral shaft fracture
with resultant deformity preventing passage of
intramedullary nail.

Figure 3. Intraoperative radiographs of right femur
following closed reduction and intramedullary nailing.
The patient was placed into Buck’s traction for
comfort. He was brought to the operating room for
trochanteric entry intramedullary nail fixation of the
right subtrochanteric femur fracture using an 8.5-mm
trochanteric entry intramedullary nail for adolescents
(Smith and Nephew; Watford, UK) (Figure 3).
Postoperatively, the patient was made weight bearing
as tolerated. A discussion about prophylactic fixation of
the left femur was had with the patient and his father.
It was emphasized that due to the deformity of the
left femur from the prior fracture, the left leg would
require an osteotomy to facilitate the intramedullary nail
passage. Given that the patient was from out of town,
he and his father elected to return home for definitive
treatment of the impending left femur fracture. The
patient was able to ambulate postoperatively and
demonstrated good pain control. He was discharged
2 days postoperatively to return home for further
recovery and rehabilitation. We were in contact with
his home orthopaedic surgeon before and after the
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Figure 4. Final follow-up radiographs of right femur
fracture at 6 months postoperatively showing bridging
callus formation and heterotopic ossification.

Figure 5. Final follow-up radiographs of left femur
impending fracture treated nonoperatively showing
remodeling of cortex and callus formation at prior
subtrochanteric lucency site.
surgery to ensure the appropriate transition of care was
coordinated. The patient’s right femur fracture went
on to form bridging callus and healing without pain
with asymptomatic heterotopic ossification (Figure
4). His left impending femur fracture was treated
nonoperatively with continued weight bearing and
observation by his home orthopaedic surgeon, and it
went on to heal without complication (Figure 5).

DISCUSSION
In the past few years, multiple case reports have been
published on atypical femur fractures in children with
OI treated with long-term bisphosphonate therapy
(Table 1). There has been increasing recognition of
atypical femur fractures in osteoporotic adults receiving
long-term bisphosphonate therapy. It is important to
consider this same possibility occurring in children
with OI.
Bisphosphonates work by inhibiting osteoclast
activity and inducing apoptosis. There are two classes
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of bisphosphonates. The first is nitrogenous, which
inhibits farnesyl diphosphonate synthase, causing
cytoskeleton disruption, loss of ruffled border, and
eventual apoptosis. The second is non-nitrogenous,
which induces osteoclast apoptosis.6 Atypical femur
fractures associated with bisphosphonate use is thought
to occur because of 1) its relationship to impaired
bone turnover secondary to osteoclast inhibition, and
2) resultant poor remodeling potential of the bone in
high-stress areas like the lateral cortex of the proximal
femur, with resultant microfractures weakening the bone
leading to eventual fatigue with complete fracture.5,7
A retrospective study compared femoral
shaft fractures within patients with OI and no
bisphosphonates to patients with OI treated with
bisphosphonates.8 It showed a trend of increasing
fractures in the subtrochanteric region among patients
treated with bisphosphonates. This study suggests that
the change in femur fracture pattern sustained by these
patients may be related to bisphosphonate usage.8
Another study retrospectively examined children
with OI who sustained femur fractures. The authors
evaluated x-rays for signs of atypical femur fracture and
stratified patients by those who did and did not receive
bisphosphonate therapy. They found that 22.0% of
those who did not receive bisphosphonate therapy had
radiographic evidence of atypical femur fractures, and
27.0% of those who did receive bisphosphonate therapy
had radiographic evidence of atypical femur fractures.
They concluded that no difference existed between the
bisphosphonates group and the non-bisphosphonates
group in terms of atypical femur fracture risk. They
found the increasing severity of disease type to
correlate with the increased risk of atypical femur
fractures.1
Patients with OI do not have the same bone quality
as osteoporotic adults, and atypical femur fracture
diagnosis was not designed for this patient population.9
Prior studies have shown that children with OI can
sustain low-energy fractures that mimic atypical femur
fractures without bisphosphonate therapy.9 However,
the changing pattern of femur fractures seen in children
treated with bisphosphonates and the increasing
prevalence of case reports detailing atypical femur
fractures in children on bisphosphonate therapy are
cause for concern. Recent literature suggests that
bisphosphonate therapy improves bone mineral density
and may lower fracture rates in children with OI.4
Bisphosphonate therapy does not appear to change
functional outcomes and bone growth or affect bone
pain as previously thought.4 Risks and benefits of
bisphosphonate therapy in pediatric patients should be
weighed carefully to understand the potential adverse
effects better.
This case report details an atypical femur fracture
and contralateral impending atypical femur fracture as
a sequela of long-term bisphosphonate therapy in a
pediatric patient with OI. To our knowledge, this is the

first described account of a simultaneous contralateral
impending atypical femur fracture in this population.
Further research is needed to determine the efficacy
and safety of bisphosphonate therapy in children with
OI. There is a large variation in the dose, the interval
between infusions, and the duration of intravenous
bisphosphonates between institutions. Consistent
treatment protocols and cumulative dose and length of
appropriate treatment guidelines need to be established
in this population. Practitioners must maintain vigilance
when detecting these impending fractures in patients
on bisphosphonate therapy and order appropriate
imaging for patients with prodromal pain.
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